Linear IgA bullous dermatosis induced by atezolizumab: a case report
https://doi.org/10.4081/dr.2024.9923
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Linear IgA Bullous Dermatosis (LABD) is a rare immune-mediated vesiculobullous disease that was reported to be induced by infections or medications. Atezolizumab is a monoclonal antibody targeting programmed cell death ligand-1 (PD-L1), it has been used to treat multiple cancers. Here, we report a case of drug induced LABD following the administration of Atezolizumab.
Bernett CN, Fong M, Yadlapati S, Rosario-Collazo JA. Linear IGA Dermatosis. 2021 Nov 20. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2022.
Lammer J, Hein R, Roenneberg S, Biedermann T, Volz T. Drug-induced linear IgA bullous dermatosis: a case report and review of the literature. Acta Dermato Venereologica. 2019 Jan 1;99(6):508-15. DOI: https://doi.org/10.2340/00015555-3154
Sibaud V, Meyer N, Lamant L, Vigarios E, Mazieres J, Delord JP. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol. 2016 Jul;28((4)):254–63. DOI: https://doi.org/10.1097/CCO.0000000000000290
Aguilar‐Duran S, Mee J, Popat S, Heelan K. Atezolizumab‐induced linear IgA bullous dermatosis. British Journal of Dermatology. 2022 Dec;187(6):e193-. DOI: https://doi.org/10.1111/bjd.21653
Yawalkar N, Reimers A, Hari Y, Hunziker TH, Gerber H, Müller U, Pichler W. Drug-induced linear IgA bullous dermatosis associated with ceftriaxone-and metronidazole-specific T cells. Dermatology. 1999;199(1):25-30. DOI: https://doi.org/10.1159/000018173
Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014 Nov;515(7528):563-7. DOI: https://doi.org/10.1038/nature14011
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
